Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bosulif

(Bosutinib Oral Tablet)

PPrism Pharmaceuticals

0

Indications

1

Total Trials

0

Active Trials

0

Competitors

2

FDA Applications

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Dementia With Lewy Bodies1 trial

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (DLB)

Completed·GGeorgetown University·Phase 2·NCT03888222·26 enrolled

Regulatory

FDA Approval Timeline[3]

Sep 4, 2012

BOSULIF

NDA NDA203341

Sep 26, 2023

BOSULIF

NDA NDA217729

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bosutinib Oral Tablet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bosutinib Oral Tablet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA217729). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Prism Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: PPrism Pharmaceuticals

Related News